EMBO Molecular Medicine (Oct 2015)

The MICA‐129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation

  • Antje Isernhagen,
  • Dörthe Malzahn,
  • Elena Viktorova,
  • Leslie Elsner,
  • Sebastian Monecke,
  • Frederike von Bonin,
  • Markus Kilisch,
  • Janne Marieke Wermuth,
  • Neele Walther,
  • Yesilda Balavarca,
  • Christiane Stahl‐Hennig,
  • Michael Engelke,
  • Lutz Walter,
  • Heike Bickeböller,
  • Dieter Kube,
  • Gerald Wulf,
  • Ralf Dressel

DOI
https://doi.org/10.15252/emmm.201505246
Journal volume & issue
Vol. 7, no. 11
pp. 1480 – 1502

Abstract

Read online

Abstract The MHC class I chain‐related molecule A (MICA) is a highly polymorphic ligand for the activating natural killer (NK)‐cell receptor NKG2D. A single nucleotide polymorphism causes a valine to methionine exchange at position 129. Presence of a MICA‐129Met allele in patients (n = 452) undergoing hematopoietic stem cell transplantation (HSCT) increased the chance of overall survival (hazard ratio [HR] = 0.77, P = 0.0445) and reduced the risk to die due to acute graft‐versus‐host disease (aGVHD) (odds ratio [OR] = 0.57, P = 0.0400) although homozygous carriers had an increased risk to experience this complication (OR = 1.92, P = 0.0371). Overall survival of MICA‐129Val/Val genotype carriers was improved when treated with anti‐thymocyte globulin (HR = 0.54, P = 0.0166). Functionally, the MICA‐129Met isoform was characterized by stronger NKG2D signaling, triggering more NK‐cell cytotoxicity and interferon‐γ release, and faster co‐stimulation of CD8+ T cells. The MICA‐129Met variant also induced a faster and stronger down‐regulation of NKG2D on NK and CD8+ T cells than the MICA‐129Val isoform. The reduced cell surface expression of NKG2D in response to engagement by MICA‐129Met variants appeared to reduce the severity of aGVHD.

Keywords